Back


09/01/2020
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD
Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selectivePPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-ALD and Friedreich’s Ataxia. It previously received Orphan Drug Designation from EMA and FDA for both conditions [...]

Download the pdf file





X

X